TxCell

company

About

TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases.

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
€12.40M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2001
Number Of Employee
51 - 100
Operating Status
Active

TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells).

The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patient
population and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
€33.90M
TxCell has raised a total of €33.90M in funding over 2 rounds. Their latest funding was raised on Feb 24, 2017 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 24, 2017 Post-IPO Equity €11M 1 Detail
Nov 26, 2012 Series C €12.40M 1 InnoBio Fund Detail
Feb 1, 2008 Series B €10.50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
TxCell is funded by 2 investors. InnoBio Fund and Bioam Gestion are the most recent investors.
Investor Name Lead Investor Funding Round
InnoBio Fund Post-IPO Equity
Bioam Gestion Series B